Daiichi Sankyo said Aug 10 it and Innovent Biologics have signed an exclusive
entrusted promotion agreement for Vifutai (quizartinib hydrochloride tablets) in
mainland China. Under the deal, Daiichi Sankyo will be responsible for clinical
development, manufacturing and supply, while Innovent obtains exclusive rights
to promote and will lead commercialization in the China market.